Drug profile · INN
lapatinib
TYKERB
lapatinib (TYKERB) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Novartis Pharmaceuticals.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01EH01
Patents linked 0
Pipeline programs 8
News articles 0
Drug details — lapatinib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 8
- Data quality
- 0.83
Quick answer
lapatinib (TYKERB) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Novartis Pharmaceuticals.
Key facts
INN lapatinib
Brand TYKERB
Mechanism Receptor protein-tyrosine kinase erbB-2 inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EH01
Originator Novartis Pharmaceuticals
Mechanism of action
Receptor protein-tyrosine kinase erbB-2 inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lapatinib?
lapatinib (TYKERB) is a receptor protein-tyrosine kinase erbb-2 inhibitor. Associated with Novartis Pharmaceuticals.
What is the brand name for lapatinib?
TYKERB is a marketed brand name for lapatinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.